Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00612274 · ClinicalTrials.gov registry record · Early Phase 1
Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation
A Early Phase 1 study of Stem Cell Transplantation, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT00612274: Completed Early Phase 1 study of Stem Cell Transplantation, sponsored by Yale University.
NCT00612274 is a Early Phase 1 study of Stem Cell Transplantation that has completed, run by Yale University. The registered enrollment target is 26 participants, below the 42-participant average among 8 other Stem Cell Transplantation trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00612274, a Early Phase 1 study of Stem Cell Transplantation, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this trial is to study the safety and efficacy of a novel regimen of sirolimus, tacrolimus and methotrexate as prophylaxis against acute graft versus host disease (GVHD) in recipients of mismatched unrelated donor stem cell grafts. Methotrexate is administered in a low dose format of 5mg/m2 on days +1,3 and 6 only.
Conditions Studied
Interventions
- DRUG Sirolimus
- DRUG Methotrexate
- DRUG tacrolimus
Study Locations (1)
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2007-10 |
| Est. Completion | 2014-10 |
| Phase | Early Phase 1 |
What the finished NCT00612274 record still lists
NCT00612274 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 42-participant average among 8 other Stem Cell Transplantation trials with a reported enrollment target (38% lower).
The record links to 1 condition, with Stem Cell Transplantation appearing as the primary indexed condition, and to 3 interventions - of which Sirolimus is the first listed.
NCT00612274 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00612274 about?
NCT00612274 is a clinical study titled "Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation". The primary objective of this trial is to study the safety and efficacy of a novel regimen of sirolimus, tacrolimus and methotrexate as prophylaxis against acute graft versus host disease (GVHD) in recipients of mismatched unrelated donor stem cell grafts. Methotrexate is administered in a low dose ...
What is the current status of trial NCT00612274?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 26 participants. The study started on 2007-10. Estimated completion is 2014-10.
What conditions does trial NCT00612274 study?
This clinical trial studies the following conditions: Stem Cell Transplantation.
What interventions are being tested in trial NCT00612274?
The interventions under investigation include: Sirolimus (DRUG), Methotrexate (DRUG), tacrolimus (DRUG).
Who is sponsoring clinical trial NCT00612274?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00612274 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stem Cell Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00612274's enrollment target sits among peer trials
26 6th of 8 higher than 3 of 8 other Stem Cell Transplantation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stem Cell Transplantation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
ACTIVE NOT RECRUITING · NA
-
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
ACTIVE NOT RECRUITING · Phase 2
-
Feasibility Neurocognitive Outcome After Transplant
ACTIVE NOT RECRUITING · NA
-
C-Reactive Protein as a Predictor of Stem Cell Transplant Complications
COMPLETED
-
Post-HSCT Medication Adherence mHealth App
COMPLETED
-
The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia